One in eight metastatic cancer hospitalizations may now be preventable. A June 2026 report published in the American Journal of Managed Care found that patients enrolled in Canopy's ePRO-based remote therapeutic monitoring program experienced a 28% relative reduction in hospitalizations compared to controls, 9.0% versus 13.0% over 18 months, with a P value of .032. That is not a trend. That is a signal oncology teams can no longer afford to ignore.

1. The 28% Reduction Is Real and Statistically Significant

Skepticism about remote monitoring outcomes data is reasonable, but this finding holds up. The AJMC report tracked metastatic cancer patients over 18 months, comparing those completing weekly electronic patient-reported outcomes (ePROs) through Canopy's platform against matched controls. The result was a hospitalization rate of 9.0% versus 13.0%, a difference with a P value of .032. That level of statistical significance, sustained across a lengthy follow-up period in a high-acuity population, gives this data real clinical weight. The mechanism matters too: weekly symptom capture creates an early-warning rhythm that routine visits simply cannot replicate.

2. Medically Complex Patients Benefit Most

Not every patient gains equally from RTM enrollment, and that is actually useful information for your practice. The AJMC findings showed the greatest hospitalization reduction among patients with high comorbidity burden, those who are already difficult to manage across fragmented care settings. For this subgroup, the number needed to treat to prevent one hospitalization was approximately 11. An NNT of 11 in an oncology population is clinically meaningful. If your practice carries a panel of medically complex metastatic patients, RTM enrollment is not a nice-to-have. It is a defensible, evidence-backed clinical priority.

3. The Financial Case Is No Longer Abstract

Health systems often ask for the business case before investing in new monitoring infrastructure. The AJMC report provides one: modeled savings of approximately $3.15 million annually per 1,000 patients enrolled. Oncology hospitalization costs are among the highest in medicine, driven by acute symptom crises, unmanaged toxicity, and delayed intervention. When weekly ePRO completion intercepts those moments before they become admissions, the downstream savings compound quickly. For administrators evaluating RTM platforms, this figure offers a credible starting benchmark for ROI modeling within your own patient population.

4. Weekly Completion Frequency Is the Critical Variable

The correlation in the AJMC report was not simply with RTM enrollment. It was specifically tied to weekly ePRO completion. Patients who consistently reported symptoms on a seven-day cadence drove the outcome difference. This means the design of your patient engagement strategy matters as much as the technology you select. Platforms that embed automated reminders, reduce friction in the reporting interface, and surface completion gaps for care coordinators in real time are not optional features. They are what separates a program with a 28% hospitalization reduction from one that produces noise.

5. Fragmented Records Undermine RTM Value

Even the best ePRO signal gets lost when it lands in a fragmented workflow. Oncology patients routinely receive care across primary care, specialty, infusion centers, and emergency departments. If RTM data from a platform like Canopy is not connected to a unified view of the patient's full clinical history, the clinician receiving a symptom alert is working without context. They cannot quickly assess whether a new pain report represents a change from baseline, a medication interaction, or a new finding requiring imaging. Structured, organized health records are the foundation that makes RTM alerts actionable rather than just audible.

6. RTM Billing Under CPT Codes Requires Structured Documentation

Remote therapeutic monitoring is now a reimbursable service under CMS, with CPT codes 98975 through 98978 covering device setup, initial monitoring, and monthly treatment management. But clean billing requires clean documentation. Each RTM encounter must reflect time spent reviewing patient-generated data and the clinical response to that data. If your team is pulling information from multiple systems to reconstruct what happened and when, billing compliance becomes a liability. Practices that invest in structured data workflows upstream reduce administrative burden downstream and protect reimbursement integrity.

7. The Oncology Nursing Workforce Is the Last Mile

Technology does not prevent hospitalizations. Nurses, APPs, and care coordinators who receive clear, organized, prioritized information do. The AJMC findings point to a care model where weekly ePRO data reaches the right clinical team member in time to act. That requires two things: a platform that surfaces high-priority symptom flags without burying them in noise, and a workflow where the clinical team has enough context to respond with confidence. Supporting your oncology nursing workforce with better information structures is not a back-office improvement. It is direct patient safety infrastructure.

8. Implementation Gaps Can Erase the Benefit Entirely

A 28% hospitalization reduction is a ceiling, not a floor. Programs that enroll patients but fail to sustain engagement, fail to integrate data into provider workflows, or fail to act on alerts in a defined timeframe will not reproduce this outcome. The Canopy data reflects a structured program with consistent completion cadence. Replicating those results requires honest implementation planning: who reviews alerts, within what timeframe, with access to what clinical history, and with what escalation protocol. RTM without implementation rigor is monitoring theater. RTM with it is one of the most impactful tools in oncology care management available today.

The evidence for remote therapeutic monitoring in oncology is no longer preliminary. A 28% reduction in hospitalizations, an NNT of 11 in high-comorbidity patients, and modeled savings of $3.15 million per 1,000 patients represent a standard of care argument, not a pilot program. The remaining question for oncology teams is not whether RTM works. It is whether the clinical and data infrastructure supporting your program is organized enough to let it.

See how MediClarity gives clinicians and patients one organized view of the full health story. Visit mediclarity.ai to learn more or request a demo.